计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity.
In Vitro
Karenitecin is a topoisomerase I inhibitor, with potent anti-cancer activity. Karenitecin inhibits cell growth of A253 cells with IC 10 , IC 50 , and IC 90 values of 0.01, 0.07, and 0.7 μM after 2 h treatment. Karenitecin induces DNA damage (0.01, 0.07, and 0.7 μM), and increases cyclin E and cdk2 protein expression in A253 cells (0.07, and 0.7 μM). Karenitecin markedly enhances the cyclin B/cdc2-associated kinase activity at low concentration, but slightly suppresses this kinase activity at higher concentration. Karenitecin inhibits several human colon cancer cell lines such as COLO205, COLO320, LS174T, SW1398 and WiDr cells, with IC 50 s of 2.4 nM, 1.5 nM, 1.6 nM, 2.9 nM, and 3.2 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Karenitecin shows maximum growth inhibition of 61% on COLO320 cells and 54% on COLO205 colon cancer cells via i.p. administration of 1 mg/kg in mice. Karenitecin (1.0 mg/kg daily × 5 i.p.) significantly suppresses growth inhibition both in the parental Pgp-negative xenografts and in the Pgp-positive xenografts. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal administration
Mice The human tumor xenografts grown in nude mice are measured twice a week in 3 dimensions with vernier calipers. The volume is calculated by the equation length × width × thickness × 0.5, and expressed in mm 3 . At the start of treatment (designated as day 0), groups of 5 to 6 tumor-bearing mice are formed to provide a mean tumor volume of approximately 150 mm 3 in each group. Doses of Karenitecin and CPT-11 for the daily × 5 schedule are administered according to the maximum tolerated dose (MTD) for tumor-bearing mice. This maximum tolerated dose is based on the occurrence of a mean weight loss of approximately 10% of the initial weight within the first 2 weeks after the start of the treatment. Recovery of the weight loss should be completed on day 14; consequently, mice are weighed on weekdays for 2 weeks and, thereafter, twice a week. The MTD is assessed in groups of 3 non-tumor-bearing nude mice per dose level . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:Topoisomerase I
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 生物碱及其衍生物 |
| 类(Class) | 喜树碱 |
| 亚类(Subclass) | 暂无 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 喜树碱 |
| 其他上位类(Alternative Parents) | 喹啉及其衍生物 吡喃吡啶类 吡啶酮类 苯类化合物 叔醇 杂芳族化合物 羧酸酯 内酰胺类 内酯 氮杂环化合物 氧环化合物 有机准金属盐 一元羧酸及其衍生物 有机氮化合物 有机光子化合物 碳氢化合物衍生物 有机氧化物 烷基硅烷 羰基化合物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 羟基苯甲酸酯 - 烷基硅烷 - 芳香族杂多环化合物 - 氮杂环 - 苯基化合物 - 喜树碱 - 羰基 - 羧酸衍生物 - 羧酸酰胺 - 杂芳香族化合物 - 烃衍生物 - 肟 - L-α-氨基酸 - 单羧酸或其衍生物 - 有机类金属盐 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机盐 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 有机硅化合物 - 氧杂环 - 吡喃吡啶 - 吡啶 - 吡啶酮 - 喹啉胺 - 三烷基醇 |
| 描述(Description) | 该化合物属于有机化合物中的喜树碱类。这类杂环化合物具有平面五元环结构,包含吡咯并[3,4-β]-喹啉单元(环A、B和C)、共轭吡啶酮单元(环D),以及α-羟基内酯环(E环)20位具有(S)构型的手性中心。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|